NCT00445198 - A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Small Cell Lung CancerSmall Cell Lung Carcinoma

Interventions

DRUG

ABT-263

"Phase 1 dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.~\- 50 patients with SCLC and non-hematologic malignancies. Enrollment is closed in this arm of the study.~Phase 2a dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.~\- 40 patients with SCLC"

Trial Locations (18)

20892

Site Reference ID/Investigator# 12343, Bethesda

28204

Site Reference ID/Investigator# 4934, Charlotte

30322

Site Reference ID/Investigator# 8324, Atlanta

37203

Site Reference ID/Investigator# 2624, Nashville

60612

Site Reference ID/Investigator# 2623, Chicago

85013

Site Reference ID/Investigator# 5261, Phoenix

85381

Site Reference ID/Investigator# 13605, Peoria

95817

Site Reference ID/Investigator# 4718, Sacramento

98405

Site Reference ID/Investigator# 6650, Tacoma

90095-7187

Site Reference ID/Investigator# 11942, Los Angeles

80045-0510

Site Reference ID/Investigator# 3755, Aurora

21231-1000

Site Reference ID/Investigator# 2625, Baltimore

02215

Site Reference ID/Investigator# 11941, Boston

Site Reference ID/Investigator# 2626, Boston

T6G 1Z2

Site Reference ID/Investigator# 7493, Edmonton

K1H 8L6

Site Reference ID/Investigator# 7635, Ottawa

LE1 5WW

Site Reference ID/Investigator# 18541, Leicester

M20 4BX

Site Reference ID/Investigator# 2622, Manchester